大行評級|瑞銀:維持萬洲國際“買入”評級及目標價6.5港元 重申為行業首選
瑞銀的研究報吿指,萬洲國際上半年銷售按年跌6%至122.93億美元,純利升81%至6.94億美元,反映了次季的銷售及純利分別按年跌4%及升88%。次季業績好過市場及該行預期,儘管內地業務較弱,但美國業務強過預期及亮麗的歐洲業務帶動季績表現。
該行稱,管理層重申計劃直到年末繼續減少美國豬的產能至每年少於1500萬頭,未來兩至三年每年少過1000萬頭。至於美國包裝肉,管理層因為成本、組合及定價的改善而對於未來的盈利能力感到樂觀。瑞銀料市場對公司業務反應正面,上調其對公司今明兩年的純利預測分別3%及1%,維持“買入”評級及目標價6.5港元,同時重申為行業首選。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.